SYN logo

SYN Synthetic Biologics, Inc.

New York Stock Exchange Arca · Biotechnology · Healthcare

$1.02
+0.01 (+0.99%)

Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on creating treatments for illnesses with significant unmet medical demands. Among its leading product candidates is SYN-004, engineered to neutralize common intravenous beta-lactam antibiotics within the digestive system. This aims to safeguard the gut microbiome, prevent Clostridium difficile infections (CDI), curb the prol…

Market Cap: $16.16Mtherivabio.com

Price

No data yet.

Social Signal Score

30
5d
30
1 mentions
—
30d
30
3 mentions
—
60d
30
3 mentions
—
90d
30
3 mentions
—
news: 3

Analyst Ratings

7 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 2Sell 0Strong Sell 0

Revenue

$0.00
$0.00
Dec 2015Jun 2026

Company Profile

CEO
Steven Shallcross
Sector
Healthcare
Industry
Biotechnology
Employees
16
Beta
1.39
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-15.06
therivabio.com